Celestoderm-B cream 0.1%, 30 g

Inflammatory skin diseases, amenable to glucocorticosteroid (GCS) therapy, eczema (atopic, pediatric, coin-like), contact dermatitis, seborrheic dermatitis, neurodermatitis, solar dermatitis, exfoliative dermatitis, radiation dermatitis, intertriginous dermatitis, psoriasis, anudenital and senile zest.

Outwardly.
CelestodermЃ-B cream should be applied in a thin layer to the affected areas 1-3 times a day, depending on the severity of the condition. In most cases, it is sufficient to apply 1-2 times a day to achieve the effect.

1 g of cream contains:
active substance: betamethasone 17-valerate - 1.22 mg (equivalent to 1 mg of betamethasone);
excipients: white soft paraffin - 150.0 mg, cetostearyl alcohol - 72.0 mg, liquid paraffin - 60.0 mg, macrogol-cetostearyl ether - 22.5 mg, phosphoric acid and sodium hydroxide - qs (in the form of 5% solution in the amount necessary to adjust the pH), sodium dihydrogen phosphate dihydrate - 3.39 mg (corresponds to 3.0 mg sodium dihydrogen phosphate monohydrate), chlorocresol - 1.0 mg, purified water - qs up to 1.0 g.

- hypersensitivity to any of the components of the drug;
- pregnancy (use of high doses, long-term treatment);
- lactation period;
- children's age - up to 6 months.

Trade name: CelestodermЃ-V

International non-proprietary name - betamethasone (betamethasone)

Dosage form:

cream for external use

Composition
1 g of cream contains:
active substance: betamethasone 17-valerate - 1.22 mg (equivalent to 1 mg of betamethasone);
excipients: white soft paraffin - 150.0 mg, cetostearyl alcohol - 72.0 mg, liquid paraffin - 60.0 mg, macrogol-cetostearyl ether - 22.5 mg, phosphoric acid and sodium hydroxide - qs (in the form of 5% solution in the amount necessary to adjust the pH), sodium dihydrogen phosphate dihydrate - 3.39 mg (corresponds to 3.0 mg sodium dihydrogen phosphate monohydrate), chlorocresol - 1.0 mg, purified water - qs up to 1.0 g.

Description
Homogeneous cream of white color, soft consistency, free of visible particles. Pharmacotherapeutic group Topical glucocorticosteroid.

ATX code: D07AC01

Pharmacological properties
Betamethasone has an anti-inflammatory and antiallergic effect by inhibiting the release of cytokines and inflammatory mediators, reducing the metabolism of arachidonic acid, inducing the formation of lipocortins with anti-edematous activity, and reducing vascular permeability.
Microdispersion of this glucocorticosteroid (GCS) in a non-greasy, odorless, non-marking, easy-to-wash cream base provides effective skin penetration and rapid onset of action.

Indications for use
Inflammatory skin diseases amenable to glucocorticosteroid (GCS) therapy, eczema (atopic, pediatric, coin-like), contact dermatitis, seborrheic dermatitis, neurodermatitis, solar dermatitis, exfoliative dermatitis, radiation dermatitis, intertriginous dermatitis, psoriasis, anudenitic zoster.

Contraindications
- hypersensitivity to any of the components of the drug;
- pregnancy (use of high doses, long-term treatment);
- lactation period;
- children's age - up to 6 months.

Method of administration and dosage
Outwardly.
CelestodermЃ-B cream should be applied in a thin layer to the affected areas 1-3 times a day, depending on the severity of the condition. In most cases, it is sufficient to apply 1-2 times a day to achieve the effect.

Side effect
When using local GCS, the following undesirable effects were observed: burning, irritation and dryness of the skin, folliculitis, hypertrichosis, acne-like rashes, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, skin atrophy, striae and prickly heat.

Special instructions and precautions
If there is no effect of treatment within 2 weeks, it is recommended to consult your doctor in order to possibly clarify the diagnosis.
If irritation or hypersensitivity reaction is noted during the use of the drug, treatment should be discontinued and the patient should be selected for adequate therapy. For secondary fungal or bacterial infections, appropriate medications should be prescribed. In the absence of a quick positive effect, the use of GCS should be discontinued until all signs of infection are eliminated.
Any side effects of systemic corticosteroids, including suppression of the function of the adrenal cortex, can also be observed when using local corticosteroids, especially in children. Systemic absorption of local corticosteroids is increased with their long-term use, in the treatment of extensive body surfaces or when using dressings, as well as in children. CelestodermЃ-B is indicated for external use only and is not intended for use in ophthalmology.

Application in pediatric practice
CelestodermЃ-B cream can be used to treat children over 6 months of age. Children may be more susceptible to the use of local GCS, which cause depression of the hypothalamic-pituitary-adrenal system (HPA) than older patients, due to increased absorption of the drug associated with a greater ratio of their surface area and body weight.
In children taking local GCS, the following side effects were noted: suppression of the function of the HPA system, Cushing's syndrome, linear growth retardation, lag in weight gain, increased intracranial pressure. Symptoms of adrenal cortex suppression in children include decreased plasma cortisol levels and lack of response to ACTH stimulation. Increased intracranial pressure is manifested by bulging fontanelle, headache, bilateral edema of the optic nerve head.

Use during pregnancy and lactation
Due to the fact that the safety of using local GCS in pregnant women has not been established, the appointment of drugs of this class during pregnancy is justified only if the benefits to the mother clearly outweigh the possible harm to the fetus. Drugs in this group should not be used in pregnant women in high doses or for a long time.
Since it has not yet been established whether GCS, with local application and systemic absorption, can penetrate into breast milk, breastfeeding or the use of the drug should be discontinued, given how much its use is necessary for the mother.

Overdose
Symptoms . Excessive or prolonged use of local GCS can cause inhibition of the function of the pituitary-adrenal system, which can lead to the development of secondary adrenal cortex insufficiency and the appearance of symptoms of hypercortisolism, including Cushing's syndrome.
Treatment . Appropriate symptomatic treatment is indicated. Acute symptoms of hypercortisolism are usually reversible. Correction of electrolyte imbalance is indicated if necessary. In the case of chronic toxic effects, a gradual abolition of GCS is recommended.

Release form
Cream for external use 0.1%. 15 g or 30 g each in aluminum tubes coated with epoxy varnish and closed with a membrane and a screw cap. One tube together with instructions for use in a cardboard box.

Shelf life is
5 years. Do not use after the expiration date.

Storage conditions Out of the
reach of children.
Store at a temperature not exceeding 25 oC.

Terms of leave
Without a prescription.